For example, Bevacizumab, a monoclonal antibody targeting VEGF (vascular endothelial growth factor) overexpression that inhibits neovascularisation and tumour growth has been shown to improve the progression-free survival (although not overall survival) when used as an adjunct to chemotherapy in ovarian cancer [46,47]. Here, VEGFA is linked to neoplasm.